My Favorite Ways to Cool Your Home Down In a Heat Wave
Did you know that heat waves kill more Americans than any other major weather event, including floods and fires? The human body can really struggle to stay hydrated and deal with suddenly high temperatures -- and the same is true of our pets as well.
Fortunately, working with smart thermostats, air purifiers, air quality sensors, smart shades and a variety of other home products has taught me a lot about quickly cooling a place down without skyrocketing your energy bills. When the worst heat strikes, here's what I recommend doing to stay healthy and cool. And if you have any elderly family nearby, make sure they're following tips like these too.
1. Use a portable air conditioner and monitor room temperature carefully
Arlo sensors can do nearly anything and are easy to move whenever you want.
Arlo
Whole-house air conditioners remain very important in heat waves, especially when combined with other cooling methods. But not all homes have whole-house AC, and in severe heat waves, they may not be enough. Another option is a smart portable air conditioner that you can plug in and move from room to room, depending on where you're spending time.
Take a look at our list of the top portable air conditioners, and you'll find models with remotes, voice assistant support, timers, dehumidifier functions and much more. Expect to spend around $400 for a good model that you can use for summers to come.
Important note: Once temperatures start rising well above 90 degrees Fahrenheit, basic ceiling fans don't really make a difference, especially when addressing health issues. It's important to focus more on home insulation and air conditioning.
In many homes, some rooms can get much hotter than others, which doesn't really help central thermostats do their job. Consider home monitoring devices that can sense temperature, like these all-in-one Arlo security sensors we tested. That way you can constantly monitoring the temperature in a particular spot (sitting room, bedroom, baby's room, etc.) and take action if it gets too high.
2. Set a strict curtain schedule for your windows
Sunlight streaming through your windows can heat up objects and air inside your home, making a heat wave worse. Close your blinds completely during the hottest temperatures for better protection. You can also search for smart blinds and curtain retrofits to let you set automatic schedules to make this process easier.
Once the outside temperature drops significantly below indoor temps, your insulation starts working against you. So, if your region experiences cooler nights, wait for the temperature difference and open windows around your home to create cool air flow.
3. Replace your HVAC filter and order an inspection
Kangaroo includes a climate sensor, aka leak detector, in its expanded eight-piece home monitoring kit.
Kangaroo
To prepare for a heat wave, you'll want to replace your home HVAC filter, which is typically located right at the fan system that pushes air around your house. It's a good idea to keep several properly sized filters nearby so you can switch them out a couple of times a year, or when you really need efficient airflow.
If you have time, you should also schedule a maintenance visit from a professional HVAC contractor. Among other things, they can test the refrigerant levels in your AC system. Refrigerant can leak out over time and make your air conditioning less efficient. Making sure you have the proper levels is important ahead of a hot period.
Read more: HVAC Maintenance Guide: What to DIY and When to Call a Pro
4. Install leak detectors and monitor for leaks
Home leaks are often associated with freezing temperatures when pipes crack in the dead of winter. But heat waves can cause an opposite, yet similar, problem: Pipes can expand and damage their valves and other components, which also leads to leaks. Also, AC units can go into overdrive and may leak more than usual in your basement or garage.
Most home security systems, like Abode, offer leak detector add-ons that you can place in susceptible areas to get alerts or alarms when water on the floor is detected. You can also find standalone units from Eufy and other brands.
5. Keep your outdoor home devices out of direct sunlight
Cutting down on drafts helps keep the cool air inside.
BanksPhotos via Getty
Shade is your friend when placing outdoor electrics like home security cameras or outside sensors -- even robot lawnmowers. High temps can wreak havoc on batteries, make sensitive electronics overheat and may even cause plastics to melt.
So when the temperature start shooting up, bring your electronics inside or into the shade until the hot spell is over. And please watch where you install your home cameras.
6. Check and replace your weather stripping
Weather stripping refers to those small strips of felt and rubber at the edges of windows and doors. They play a vital role in home insulation: When they wear down or get ripped off, the gaps notoriously cause drafts. That's unpleasant in wintertime, but during a heat wave it can sap all the cool air that your AC has created, keeping your home from cooling down fully and increasing the risk of heat-related health problems.
Prep for heat waves by checking weatherstripping and blocking any drafts from worn materials. You can find weather stripping yourself for a DIY project, but it's important to get the right kind to match your doors and windows.
7. Find cooler alternatives for cooking
Keep kitchens calm and cool during a heat wave.
Brothers91 via Getty
Cooking and baking produce a lot of heat in the kitchen, so you may want to reduce those activities during a heat wave. That's why we have an entire guide on how to keep your kitchen cool when temperatures rise, including prepping meals beforehand or cooking late in the evening. Also, this may be a great time to check out meal delivery services.
Read more: Don't Turn Your Oven on During a Heat Wave. Do This Instead
8. Search for electronics to unplug and stop using
Large electronics can produce a lot of background heat even when they're in standby mode. When the heat gets really bad, try unplugging larger electronics entirely. That can include A/V receivers, game consoles, desktop computers and televisions -- depending on what you plan to use that day.
On that note, refrain from running heat-producing appliances like dishwashers and dryers, or at least wait until nighttime when temperature drops.
Read more: Heat Wave: Keep Your Phone From Overheating in Record Temps
9. Replace your lighting with smart lights
Alexa Emergency Assist replaced Alexa Guard.
Amazon
There's one other surprising part of the home that produces a lot of heat -- your incandescent lights, which are terribly inefficient at using energy (touch one to find out). Newer LEDs (light-emitting diodes) found in smart lights create almost no heat and tend to last much longer.
The key is finding high-quality, affordable smart lights, which is why you should head over to our list of the best smart lights available. Switch out those sweaty lights with LEDs and your house will start feeling cooler.
10. Create easy access to emergency medical services
An Echo can help during a heat wave emergency.
Amazon
If it looks like someone is suffering from heatstroke or a similar condition, it's important to get medical attention immediately to help them out. Signs include lots of sweating accompanied by headache, nausea and disorientation. If someone shows problems like these, get them in a cool spot and contact emergency services. You can also bathe their feet in cool water to help them get relief.
Some home security plans can make this easier. The Alexa Emergency Assist plan ($6 per month) is a good option, since it works with existing Alexa speakers and lets you immediately call for help and notify family emergency contacts with a command. That can be especially important for elderly relatives who may live alone and are more susceptible to heat-related conditions.
For more temperature management choices, visit our guide to the best smart thermostats and look at the top DIY security monitoring systems. It's also a good idea to brush up on heatstroke safety and how to stay safe when air quality is really bad.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
Inflammation Link Allergy, Asthma, and Depression?
The prevalence of depression is consistently higher in persons with asthma than in persons without it, according to experts, and a review of 24 studies also found that allergic rhinitis was associated with higher odds of depression or anxiety. Over the past two decades, multiple investigators have looked beyond emotional or lifestyle triggers of depression in chronic airway or allergic conditions, focusing instead on eco-biological ones. This has led to inflammation being identified as the common denominator in all three — allergies, asthma, and depression. As the understanding of how inflammation, as measured by an increase in immune cells, cytokines, and other biomarkers, affects neural signaling continues to improve; potential implications for clinical practice are beginning to emerge, experts say. Evolutionary 'Mismatch' One line of inquiry that implicates inflammation in depression, chronic airway trouble, and allergies, involves the microbiome and how modern living has altered it. 'There's essentially an evolutionary mismatch in the modern world,' Charles Raison, MD, professor of psychiatry and human ecology at the University of Wisconsin - Madison, told Medscape Medical News in an interview. 'We've made the world so clean we deprive ourselves — especially in early life when allergies and asthma tend to develop — of contact with microorganisms that train the immune system not to fire off at things they don't need to fire off about.' In a review of literature published in 2013 on immune function titled, Inflammation, Sanitation, and Consternation , Raison and his coauthors concluded that measured exposure to certain microorganisms and their antigens could offer both prevention and intervention for depression. 'Our current challenge is to determine who among those with allergies is at highest risk of developing depression, and why,' Christopher Lowry, PhD, a coauthor on the paper with Raison, told Medscape Medical News . Lowry is a professor of integrative physiology and associate chair of faculty affairs at the University of Colorado Boulder. 'Old Friends' Raison and Lowry's collaboration follows on from the 'Old Friends' work of Graham Rook, a coauthor of their review study, and an emeritus professor of medical microbiology at the University College London in London, England. 'The association between allergies and depression is embedded in the 'Old Friends' or Biodiversity Hypothesis which posits that reduced exposures to diverse microbial environments, which is typical of modern urban lifestyles, increases risk of allergies, anxiety disorders, and depression,' Lowry told Medscape Medical News . Because the commensal microorganisms in the gut are one of the major types of microbial 'Old Friends' that can induce anti-inflammatory and immunoregulatory responses, Lowry said, 'Those who lack diverse microbial exposures, including diverse microbial exposures in the gut microbiome, are thought to be at higher risk of inflammatory disease and inflammation-associated conditions.' Similarly, 'we have shown that this response is greater in persons who grow up in an urban environment, without daily exposure to pets, relative to persons who grow up on a farm, with daily exposure to farm animals,' said Lowry, whose research on the immune effects of exposure to animals was published in the Proceedings of the National Academies of Science . Other categories of microbial 'Old Friends,' according to Lowry, are environmental saprophytes found in soil, mud, and unpurified water, and so-called 'Old Infections' such as the hepatitis A virus or Salmonella . Rook has gone so far as to say that these microbial inputs, 'are absolutely crucial in early life, but continue to be important in adulthood and old age.' Raison added, 'These microbes don't cause illnesses, they are the teachers of tolerance, is how we used to say it. When we began to institute a bunch of modern sanitation and medical practices, on the plus side people stopped dying in youth. Huge win. But we didn't see we were tossing out the good with the bad, and we've lost our exposure to these environmental immunoregulatory organisms that suppress inflammation.' In the past 40 years, incident rates for asthma in the US have doubled according to federal data. A third of persons in the US now have an allergy of some kind, these data also showed. Rates of depression are also at their highest, according to a probability-based Gallup survey of 100,000 adults in the US. In 2023, the survey found that 29% of US adults had been given a diagnosis of depression in their lifetime. Microbial Population Health Initiative The 'Old Friends' theory was tested in Finland for the decade between 2008 and 2018, when a population health initiative to increase exposures to diverse microbial environments led to a reduction in hospitalizations for asthma by half nationally and a 50% drop in the number of food allergies reported in Finnish schools and daycares. The results were published in 2021 in The Journal of Allergy and Clinical Immunology . Depression rates for this time period in Finland are not currently available. 'This was hot, sexy stuff back 20 years ago, but nobody figured out the magic bullet to end all allergies and asthma, so like a lot of things in mental health, it didn't come too much,' Raison said. 'It's gone through fads, like the probiotic fad. But another question would be, what if you were to re-expose kids to these kinds of microbes that train the immune system not to be so agitated, would you lower rates of depression and suicide in adults? Those studies were never done.' Lowry, however, now studies whether the microorganism, Mycobacterium vaccae ATCC 15483, which has been identified as having anti-inflammatory, immunoregulatory, and stress-resilience properties, can be leveraged to protect humans from the effects of inflammation. In a study that was published earlier this year in Brain, Behavior and Immunity , Lowry and his colleagues found M vaccae reduced biomarkers of neuroinflammation and anxiety-like behavior in animals. It also reduced several indicators of obesity such as plasma leptin concentrations and adipose tissue. 'We hope to conduct clinical trials in the next 2-5 years to determine if treatment with mycobacteria can reduce inflammation and promote stress resilience in humans,' Lowry said. 'Future studies should evaluate if mycobacteria or other 'Old Friends' can prevent or treat anxiety and depression.' Inflammation Is Bidirectional If depression in asthma and allergies is at least partially biological, then there are implications for clinical practice, according to one expert. 'The default for physicians is usually that it's hard to have a chronic disease, and that's why their patients are depressed,' Melissa Rosenkranz, PhD, told Medscape Medical News . 'But if they understand that there is a biology that underlies it, that the immune dysregulation that's giving rise to the disease is also contributing to the depression, and that they can do something about that — if we can target those signaling pathways, then we can be treating both simultaneously.' Rosenkranz is an associate professor of psychiatry at the University of Wisconsin - Madison and is the distinguished chair of contemplative neuroscience at the Center for Healthy Minds. Her field is psycho-neuroimmunology, which focuses on interactions between the mind, brain, and immune system. Whether inflammation is the mechanism of action or a symptom in both asthma and depression is something she and her colleagues have studied. 'It goes in both directions,' Rosenkranz said. 'We've done that research.' Alterations in Neural Signaling Their first and second studies involved scanning study patients' brains before and after their airways were challenged with an inflammatory antigen and comparing those results to the before and after scans of the brains of participants exposed to methacholine, which does not irritate, but does constrict, the bronchial passages, making it difficult to breathe. A third study introduced an inflammatory agent to a micro region of the bronchial passages. 'All three studies showed what was happening in the brain was different in the inflammatory context,' Rosenkranz said in the interview. Specifically, Rosenkranz and her colleagues discovered that the brain's salience network — the part that prioritizes which stimuli, both internal and external to the body, require the brain's attention most — responded differently to emotional information when the immune system had been activated. They found that the more the salience network was engaged during psychological stress, the more the inflammatory response in the airway was activated, even without exposure to allergy triggers. 'Our results identify a specific inflammatory pathway linking asthma-related airway inflammation and emotion-related neural function,' Rosenkranz and her coauthors wrote in their study, published in The Journal of Allergy and Clinical Immunology . An immune pathway common to both depression and the airway inflammatory response in asthma is the T helper cell 17 (TH17) response, according to Rosenkranz, whose work has shown that the TH17 response is amplified in the lung during stress. Activity in the TH17 pathway is also elevated in people with depression, according to Rosenkranz, and TH17 is also less responsive to common asthma medications and is associated with treatment-resistant depression. 'There are probably multiple pathways through which [inflammation] happens, so I don't want to claim that this is the only one, but I think it's one among a few that may provoke inflammation in the brain,' Rosenkranz said. 'And inflammation has been shown to be part of the pathophysiology of depression. It's also part of the cascade that gives rise to Alzheimer's disease and other forms of dementia.' Rosenkranz's latest study is on how an asthma exacerbation can lead to inflammation in the brain, and whether those changes might set the stage for dementia. 'It's possible that depression is along the same trajectory as dementia,' Rosenkranz said. 'As you get on later in life, you see the cognitive decline. With nearly 10% of the population having asthma, this is a really important public health question.' Rosenkranz said she doesn't want to be an alarmist. 'I'm not suggesting that everybody who has depression has inflammation in their brain,' she said. As the field searches for an immune-signaling pathway that, if targeted with drugs, could improve asthma, allergies, prevent asthma-related depression, and possibly protect the brain, Rosenkranz said that for now, 'Physicians should evaluate the emotional well-being of their patients and work closely with mental health professionals to address mental and physical symptoms in tandem, so that they can best serve their patients.' They need to understand that depression in patients with asthma or allergy could be a symptom of, not a reaction to their diagnosis, she said.
Business Journals
an hour ago
- Business Journals
3 simple steps for employers to lower health care costs and ensure better employee care
It's no secret that the current health care system is unsustainable. Nearly half of Americans receive health care coverage through their employer and over the past two decades, employer-sponsored health care costs have risen by over 200%. Many businesses can no longer front the costs — and the burden is being shifted onto employees. The result? Health care has become unaffordable for many working Americans — for some employees cost shifting has made engaging care unaffordable and 40% of American adults are struggling with medical debt — a shockingly high number. Despite this astronomical rise in cost, most brokers and benefits consultants haven't changed the solutions they present to clients in decades. In our experience, only about 5-10% of brokers are offering their clients innovative alternatives and even fewer have fully embraced a different approach, leading to poor implementation and support when they do try something new. The reality is that health care operates as an inefficient market. Unlike most industries, higher costs do not necessarily equate to higher quality care — in fact, it can often be the opposite. We believe that by being proactive, transparent and strategic, employers can reverse this trend by reducing costs while ensuring their employees receive top-quality care. However, achieving transformational results demands a completely different approach. The four of us have spent years in this industry and have tailored a unique approach that enables us to achieve superior results. We've seen what works and what doesn't and the ineffective options continually peddled to employers. That's why we've joined forces to help employers to take control of their health care spend and save real money. Our approach We don't believe in a one-size-fits all health plans and we partner with HR leaders to bring their health care strategy to life while directly administering the change. This includes educating employees on what they need to know to make the most of their benefits. When you show people exactly how they can receive better care at a lower price, everyone wins. Our model is built on three pillars: education, pharmacy platform and Medicare Plus. Education: We empower members to navigate the health care system effectively and steer them towards high quality and cost-effective options. Navigating the health care system is hard and we take a hands-on approach, which helps members understand their choices and make informed decisions. This extra effort improves health outcomes while ensuring the best experience possible. According to publicly available data compiled by Image360, CT scans in Tampa, Florida, are typically billed between $4,500 and $9,700. Even after PPO discounts, health plan members and businesses still pay $2,200 to $4,800. The problem is, there's little transparency in pricing and high cost doesn't guarantee high quality. Imagine360 changes that. With Imagine360, the average cost for the same CT scan at the same facility drops to under $200. This translates to significant savings for the employee and the business. Pharmacy platform: Pharmacy spend is the fastest-growing expense when it comes to a health plan. Traditional solutions often lack transparency and instead function as profit centers. We craft innovative solutions to manage pharmacy costs, ensuring that members have access to affordable medications without compromising on quality. Medicare Plus: We provide a thoughtful alternative to conventional PPOs. This model offers robust coverage at significantly lower costs by anchoring reimbursements to fair, Medicare-based rates. The above approach collectively has proven to cut costs by nearly 25% on average. Through this approach, we've reduced the cost of health care so drastically that some clients now offer no-cost health care to all of their employees. At a time when most companies are forcing employees to pay upwards of thousands of dollars per month on health insurance premiums, our clients pick up the full cost of premiums for their employees. This difference is life-changing for many families. By adopting a three-pillar approach to health care benefits, these businesses have become highly sought-after employers in their communities. And it's not just beneficial for employees — it's advantageous for the health plan as well. When health care premiums are overpriced, only the highest utilizers enroll, which makes sense; you would only pay thousands of dollars a month in premiums if you anticipated high health care expenses. However, when coverage is affordable and well-structured, everyone participates, creating a healthier, more predictable and sustainable plan. If this sounds too good to be true, you're not alone. One employer came to us frustrated and skeptical. Every broker had pitched the same traditional solutions, none of which solved their problem. Their chief financial officer knew that if they could not control hospital claims costs, the business would be in trouble. We introduced Medicare Plus pricing as a strategic solution. We helped manage the learning curve for the first few months — but once leadership committed to the solution, the plan started working. Three years in, premiums, deductibles and copays have all dropped. Employees are getting better coverage, and the company has even added new benefits — while most of their peers are cutting back. Using an independent TPA Working with an independent third-party administrator (TPA) opens the door to a different and better playbook. Yes, it takes more work upfront — more education, communication, teamwork — but the payoff is worth it: a more flexible employee benefits solution that can lead to better care, lower costs, and long-term consistency. No more carrier swaps or yearly overhauls. We currently support 25 clients on this platform. With dedicated service teams, personalized enrollment education and long-term strategies, we help employers innovate — without impacting employee satisfaction. The result is a smoother, more positive experience. The road ahead We're all fighting the same fight: pushing back against a system that hides cost, limits choices, wastes money and is driving people to choose little or no coverage due to cost. But it doesn't have to be this way. With a three-pronged approach including employee education, pharmacy and Medicare Plus pricing, we're helping employers take back control of their health care costs. By putting people first and staying committed to value-based solutions, employers and brokers can finally break free from the old playbook — and build something better. McGriff is a Marsh & McLennan Agency LLC Company. Our solutions include commercial property and casualty, corporate bonding and surety, cyber, executive risk, management and professional liability, captives and alternative risk transfer programs, employee benefits, small business and personal lines insurance.
Yahoo
an hour ago
- Yahoo
Early data suggest Roche's NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A
Positive phase I/II data presented at the 2025 International Society on Thrombosis and Haemostasis (ISTH) Congress show NXT007 achieved no bleeds requiring treatment in the highest dose groups in people with haemophilia A1 The NXT007 clinical development programme aims to normalise haemostasis and minimise treatment burden2,3 Three phase III clinical studies on NXT007, a next-generation bispecific antibody, set to begin in 20261 Basel, 23 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive phase I/II data on NXT007 in people with haemophilia A, supporting its progression into phase III clinical development. NXT007 is a next-generation investigational bispecific antibody, engineered by Chugai, a member of the Roche Group. Early data from the NXTAGE study suggest that NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A (without factor VIII inhibitors). NXT007 showed a tolerable safety profile with no thromboembolic events reported so far.1 These results were featured as an oral presentation at the 2025 International Society on Thrombosis and Haemostasis (ISTH) Congress, 21-25 June, Washington D.C., United States.1 'These NXT007 data are promising for people with haemophilia A and underscore our ongoing commitment to advancing care and addressing the real-world challenges faced by this community,' said Levi Garraway, MD, PhD, Roche's Chief Medical Officer and Head of Global Product Development. 'Hemlibra established a new standard of care, and our focus is to continue to deliver breakthrough innovation that might ultimately help people with haemophilia to live their lives in a manner unaffected by this condition.' NXT007 leverages the Roche Group's expertise in haemophilia A and bispecific antibody development. Our goal is to bring a next generation prophylactic to our portfolio, offering greater therapeutic choice, sustained, elevated bleed protection and reduced treatment burden with factor independence - to allow patients to experience freedom from constant vigilance and have confidence in bleed protection. NXT007 will be further evaluated in a robust clinical development programme, including ongoing phase I/II clinical trials, with additional phase II data expected later this year. There are also three phase III studies currently planned for 2026, including a phase III head-to-head study with Roche's Hemlibra, the first available prophylactic treatment that can be administered subcutaneously and with flexible dosing options (every week, two weeks or four weeks).4,5 Part B of the phase I/II NXTAGE study, conducted by Chugai, in Japan, Taiwan and South Korea, is evaluating the safety, pharmacokinetics, pharmacodynamics and efficacy of prophylaxis with NXT007 in people with haemophilia A without factor VIII inhibitors who had not been previously treated with Hemlibra® (emicizumab).1 Thirty participants (from 12 to 65 years of age) were enrolled in four cohorts (B-1 to B-4) to receive ascending doses of subcutaneous NXT007 every two-to-four weeks during the maintenance period (following four-to-six weeks of loading doses). In presented data from the primary analysis, no treated bleeds were observed with NXT007 in the highest dose cohorts (B-3 and B-4). NXT007 was well tolerated, with no thromboembolic events observed so far.1 About NXT007NXT007 is a next-generation investigational bispecific antibody, being investigated as a prophylactic (preventive) treatment option for people with haemophilia A.1,2,3 NXT007 was engineered by Chugai – a member of the Roche Group – built on Hemlibra® (emicizumab)'s framework, with the aim of optimising factor VIII-mimetic activity and half-life, to further enhance potency, efficacy, dosing and administration convenience. NXT007 brings together factor IXa and factor X, proteins required to activate the natural coagulation cascade.1,2,3 NXT007 is being studied in a robust clinical development programme exploring its potential to achieve sustained elevated bleed protection equivalent to people who do not have haemophilia A (sustained haemostatic normalisation), and reduced treatment burden with factor independence, offering people living with haemophilia A greater therapeutic choice.1,2,3 About haemophilia AHaemophilia A is an inherited, serious disorder in which a person's blood does not clot properly, leading to uncontrolled and often spontaneous bleeding. Haemophilia A affects around 900,000 people worldwide.6,7 People with haemophilia A either lack or do not have enough of a clotting protein called factor VIII. In a healthy person, when a bleed occurs, factor VIII brings together the clotting factors IXa- and X, which is a critical step in the formation of a blood clot to help stop bleeding. Depending on the severity of their symptoms, people with haemophilia A can bleed frequently, especially into their joints or muscles.8 These bleeds can present a significant health concern as they often cause pain and can lead to chronic swelling, deformity, reduced mobility and long-term joint damage.9 A serious complication of treatment is the development of inhibitors to factor VIII replacement therapies. Inhibitors are antibodies developed by the body's immune system that bind to and block the efficacy of replacement factor VIII, making it difficult, if not impossible, to obtain a level of factor VIII sufficient to control bleeding.6 About Roche in haematologyRoche has been developing medicines for people with malignant and non-malignant blood diseases for more than 25 years; our experience and knowledge in this therapeutic area runs deep. Today, we are investing more than ever in our effort to bring innovative treatment options to patients across a wide range of haematologic diseases. Our approved medicines include MabThera®/Rituxan® (rituximab), Gazyva®/Gazyvaro® (obinutuzumab), Polivy® (polatuzumab vedotin), Venclexta®/Venclyxto® (venetoclax) in collaboration with AbbVie, Hemlibra® (emicizumab), PiaSky® (crovalimab), Lunsumio® (mosunetuzumab) and Columvi® (glofitamab). Our pipeline of investigational haematology medicines includes T-cell engaging bispecific antibody cevostamab, targeting both FcRH5 and CD3 and Tecentriq® (atezolizumab). Our scientific expertise, combined with the breadth of our portfolio and pipeline, also provides a unique opportunity to develop combination regimens that aim to improve the lives of patients even further. About Roche Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. For over 125 years, sustainability has been an integral part of Roche's business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit All trademarks used or mentioned in this release are protected by law. References[1] 1. Shima M, et al. NXT007 Prophylaxis in Emicizumab-Naive Persons with Hemophilia A without Inhibitor: Phase I/II Study (NXTAGE) Presented at International Society on Thrombosis and Haemostasis (ISTH) congress; 2025 June. Abstract OC.20.3.[2] Shima M, et al. Safety, Pharmacokinetics, and Pharmacodynamics of Single Subcutaneous Injection of NXT007, an Emicizumab-Based Next-Generation Bispecific Antibody, in Healthy Volunteers (NXTAGE Study). Presented at: International Society on Thrombosis and Haemostasis (ISTH) Congress; 2023 July 28. Abstract OC 69.4. [3] Teranishi-Ikawa Y., et al. A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a non-hemophiliac state. Journal of Thrombosis and Haemostasis. 2023; doi: 10.1016/ Hemlibra SmPC [Internet; cited 2025 June] Available from: [5] FDA Prescribing Information [Internet; cited 2025 June]. Available from: [6] Srivastava A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26 (Suppl 6): 1-158.[7] Iorio A, et al. Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males. Ann Intern Med. 2019;171(8):540-546.[8] NHS. Symptoms of haemophilia [Internet; cited 2025 June]. Available from: [9] Franchini M, et al. Haemophilia A in the third millennium. Blood Rev. 2013; 179-84. Roche Global Media RelationsPhone: +41 61 688 8888 / e-mail: Hans Trees, PhDPhone: +41 79 407 72 58 Sileia UrechPhone: +41 79 935 81 48 Nathalie AltermattPhone: +41 79 771 05 25 Lorena CorfasPhone: +41 79 568 24 95 Simon GoldsboroughPhone: +44 797 32 72 915 Karsten KleinePhone: +41 79 461 86 83 Nina MählitzPhone: +41 79 327 54 74 Kirti PandeyPhone: +49 172 6367262 Yvette PetillonPhone: +41 79 961 92 50 Dr Rebekka SchnellPhone: +41 79 205 27 03 Roche Investor Relations Dr Bruno EschliPhone: +41 61 68-75284e-mail: Dr Sabine BorngräberPhone: +41 61 68-88027e-mail: Dr Birgit MasjostPhone: +41 61 68-84814e-mail: Investor Relations North America Loren KalmPhone: +1 650 225 3217e-mail: Attachment Media Investor Release phase I_II data on NXT007 EnglishError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
